ClinicalTrials.gg
RecruitingNCT04604522Updated Oct 9, 2026

Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome

An observational study in Bronchiolitis Obliterans, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 2 months later.
Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Bronchiolitis Obliterans with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Bronchiolitis Obliterans · United States.

Started
2020
with 2 others
Observational
8 of 34
3 open now
Registered
29th of 34
by date
Lead sponsor
2 of 34
M.D. Anderson Cancer Center

Among the 34 studies in Bronchiolitis Obliterans with a site in United States, this one is one of 3 that started in 2020, is one of 8 observational ones, and was the 29th registered.

Bronchiolitis Obliterans

82 studies on the registry are indexed under Bronchiolitis Obliterans; 9 are open to participants now.

Browse Bronchiolitis Obliterans studies →

Open to participants now

5 of the 34 studies in Bronchiolitis Obliterans with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Bronchiolitis Obliterans studies recruiting now, 5 set no upper age limit and 4 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Bronchiolitis Obliterans with a site in United States, or all of them as a file.
02

Study summary

This study investigates a type of cell, called abnormal clonogenic epithelial cells, in patients with bronchiolitis obliterans syndrome who have had an donor stem cell transplant or a lung transplant. Learning more about clonogenic cells in these patients may help doctors to detect signs of bronchiolitis obliterans syndrome earlier in future patients.

Read the detailed description

PRIMARY OBJECTIVE:

I. To characterize epithelial cell phenotypes in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) and in lung transplant recipients at Houston Methodist who have bronchiolitis obliterans syndrome (BOS).

OUTLINE:

Patients undergo collection of blood samples and 3 brushings of the airway during standard of care (SOC) bronchoscopy. After the bronchoscopy, patients undergo 2 nasal brushings (swabs). Patients' medical records are also reviewed for data collection.

After completion of study, patients are followed for up to 1 year.

03

Conditions studied

  • Bronchiolitis Obliterans
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with BOS who have undergone an allo-HCT or lung allograft.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Allo-HCT recipients undergoing a bronchoscopy at MDACC who consent to undergoing study airway brushings in addition to clinically indicated bronchoscopic procedures (e.g. bronchoalveolar lavage)

    • 5 patients with advanced BOS - (FEV1) =\< 75% predicted and meeting other National Institutes of Health (NIH) criteria (FEV1/forced vital capacity [FVC] ratio 0.7, presence of air trapping or [GVHD] of another organ)
    • 5 patient with early BOS - at least 10% decline in FEV1 from baseline values, with FEV1 >= 75% predicted, and 1 high-risk feature:

      • Active systemic chronic GVHD with new early airflow obstruction OR
      • Respiratory viral infection in last three months with resolution of viral symptoms but new airflow obstruction
    • 3 patients with no pulmonary impairment (FEV1 within 5% of baseline values)
  • Lung allograft recipients undergoing a bronchoscopy at Houston Methodist who consent to undergoing study airway brushing sin addition to clinically indicated bronchoscopy procedures

    • 5 patients with BOS Stage 2 or higher (>= 35% decline in FEV1 from baseline values)
    • 5 patient with BOS Stage 0p or 1 (10-35% decline in FEV1 from baseline values)
    • 3 patients undergoing screening bronchoscopy without decline in FEV1
    • patients with undiagnosed lung cancer and diagnosed by pulmonary function testing (FEV1/FVC less than the lower limit of normal with >20 pack-year history of smoking)

Exclusion criteria

Exclusion Criteria:

  • Bronchoscopy performed on emergency basis for life-threatening issues as opposed to routine diagnostic testing
  • Patient unwilling to give consent for study airway brushings
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Ancillary-correlative (biospecimen collection, chart review)

    Patients undergo collection of blood samples and 6 brushings of the airway during SOC bronchoscopy. Patients' medical records are also reviewed for data collection.

    Procedure: Biospecimen Collection · Other: Medical Chart Review

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood, airway brushings.

  • OtherMedical Chart Review

    Patients' medical records are reviewed

    Also known as: Chart Review

06

What researchers measure

Primary outcomes

  1. Proportion of abnormal epithelial cells between patients with bronchiolitis obliterans syndrome and those without

    The relationship between the proportion of abnormal cells and degree of air trapping and lung abnormalities will be described through simple correlation. Exploration of non-linear relationships or rank-based summaries will be considered as appropriate.

    Time frame: Up to 1 year

Secondary outcomes

  1. Comparison of epithelial cell populations in allogeneic hematopoietic cell transplant recipients and lung graft recipients

    The relationship between the proportion of abnormal cells and degree of air trapping and lung abnormalities will be described through simple correlation. Exploration of non-linear relationships or rank-based summaries will be considered as appropriate.

    Time frame: Up to 1 year

07

Study locations

1 of 1 sites recruiting
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Ajay Sheshadri · Contact713-792-6238
    • Ajay Sheshadri · Principal investigator
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2020 (actual). Primary completion is estimated for Mar 2028, 91 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Mar 2026 → Mar 2028 and completion Mar 2026 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2020
First posted
Oct 27, 2020
StartActual
Aug 27, 2020
Primary completionEst.
Mar 31, 2028was Mar 2026
CompletionEst.
Mar 31, 2028was Mar 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 31, 2026→Mar 31, 2028
Oct 9, 2026
Study completion
Mar 31, 2026→Mar 31, 2028
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Mar 31, 2026→Mar 31, 2028
    Study completion Mar 31, 2026→Mar 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04604522
Responsible party
Sponsor
First posted
Oct 27, 2020
Start date
Aug 27, 2020
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Ajay Sheshadri
Contact
asheshadri@mdanderson.org
713-792-6238
Ajay Sheshadri
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion